The rally still left many shareholders in negative territory as the stock is down sharply over the last year.
Investors were generally happy with the second-quarter results that Incyte announced on the last day of July. That report showed continued growth for the blockbuster Jakafi drug and steady contributions from Iclusig, which treats certain types of leukemia. Overall, product sales grew 29%.
Future revenue gains should continue to flow from the recent U.S. approval for its Olumiant rheumatoid arthritis drug. Looking further out, executives are optimistic about a pipeline that includes a few promising late-stage candidates. None of these are expected to replace the revenue that investors had hoped Incyte would see from its failed epacadostat lung cancer therapy trial. But, with very little debt on its books, the company has time and resources to continue directing toward those next potential hit treatments.